Clinical Trial Award Recipients
There is an urgent need for new and improved therapies for ALS. To help "de-risk" the drug development process, we are proud to support early-stage clinical trials of new and repurposed treatments like these through our Clinical Trial Awards.
2022 Recipient
Laura Ranum, Ph.D., University of Florida
Safety and Therapeutic Potential of Metformin for C9orf72 ALS
LEARN MORE ABOUT OUR 2022 RECIPIENT
2021 Recipients
Daniel Fowler, M.D., Rapa Therapeutics
RAPA-501 Hybrid TREG/Th2 Cell Therapy of ALS
Eran Hornstein, M.D., Ph.D., Weizmann Institute of Science, Israel
Repurposing Enoxacin Therapy for Patients with ALS
Richard Robitaille, Ph.D., University of Montreal, Canada
Target NMJ to Maintain Motor Functions in ALS
Barbara Smith, Ph.D., University of Florida
Acute Adenosine Receptor Antagonism to Promote Breathing Plasticity in ALS
